{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:26:06Z","timestamp":1759940766725},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,3,2]],"date-time":"2012-03-02T00:00:00Z","timestamp":1330646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In Australia bufexamac is mainly used for pharmacist\u2010initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for bufexamac\u2010containing preparations be revoked throughout the European Union because of the risk of severe allergic contact dermatitis. We retrospectively reviewed the patch test database at the Skin and Cancer Foundation Inc. and identified 19 cases of positive reactions to bufexamac (5% petrolatum) from 451 people patch tested. The bufexamac reaction was deemed relevant to the presenting dermatitis in 13 of 19 (68%) patients. Bufexamac allergic contact dermatitis is under\u2010reported in the English literature. We wish to emphasise the severity and the unusually polymorphic eruptions observed in some of the cases. Clinicians should consider the possibility of allergic contact dermatitis to bufexamac\u2010containing preparations in all patients where there is a history of exposure, even if used for only a short time.<\/jats:p>","DOI":"10.1111\/j.1440-0960.2012.00876.x","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T15:33:16Z","timestamp":1330961596000},"page":"207-210","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Allergic contact dermatitis to topical preparations of bufexamac"],"prefix":"10.1111","volume":"53","author":[{"given":"Yan","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1997.tb00272.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02118.x"},{"key":"e_1_2_6_4_2","unstructured":"European Medicines Agency.European Medicines Agency recommends revocation of marketing authorisations for bufexamac. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/04\/WC500089623.pdf. (Accessed 9 Oct 2010.)"},{"key":"e_1_2_6_5_2","unstructured":"European Medicines Agency.Questions and answers on the revocation of the marketing authorisations for medicines containing bufexamac. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Bufexamac_107\/WC500089665.pdf. (Accessed 9 Oct 2010.)"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00341.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1999.tb05992.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-923320"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1994.tb01926.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2007.01271.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-37850"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-008-1656-2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017996"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1998.tb05936.x"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-0960.2012.00876.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-0960.2012.00876.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T03:01:32Z","timestamp":1698721292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-0960.2012.00876.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,2]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1440-0960.2012.00876.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-0960.2012.00876.x","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,2]]},"assertion":[{"value":"2012-03-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}